Precision medicine applications for severe asthma

Abraham I., Alhossan A., Lee C.S., Kutbi H., and MacDonald K. 2016. ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: Systematic review. Allergy. 71:593–610.

Aron J.L. and Akbari O. 2017. Regulatory T cells and type 2 innate lymphoid cell-dependent asthma. Allergy. 72:1148–1155.

Barnes P.J. and Adcock I.M. 2009. Glucocorticoid resistance in infl ammatory disease. Lancet. 373:1905–1917.

Bel E.H., Wenzel S.E., Thompson P.J., Prazma C.M., Keene O.N., Yancey S.W., Ortega H.G., and Pavord I.D. 2014. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 371:1189–1197.

Berkman N., Avital A., Breuer R., Bardach E., Springer C., and Godfrey S. 2005. Exhaled nitric oxide in the diagnosis of asthma: Comparison with bronchial provocation tests. Thorax. 60:383–388.

Bleecker E.R., FitzGerald J.M., Chanez P., Papi A., Weinstein S.F., Barker P., Sproule S., Gilmartin G., Aurivillius M., Werkström V., and Goldman M. 2016. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 388:2115–2127.

Bleecker E.R., Wechsler M.E., Mark FitzGerald J., Menzies-Gow A., Wu Y., Hirsch I., Goldman M., Newbold P., and Zangrilli J.G. 2018. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur. Respir. J. 52:1800936.

Bousquet J., Mantzouranis E., Cruz A.A., Aït-Khaled N., Baena-Cagnani C.E., Bleecker E.R., Brightling C.E., Burney P., Bush A., Busse W.W., Casale T.B., Chan-Yeung M., Chen R., Chowdhury B., Chung K.F., Dahl R., Drazen J.M., Fabbri L.M., Holgate S.T., Kauffmann F., Haahtela T., Khaltaev N., Kiley J.P., Masjedi M.R., Mohammad Y., O’Byrne P., Partridge M.R., Rabe K.F., Togias A., Van Weel C., Wenzel S., Zhong N., and Zuberbier T. 2010. Uniform definition of asthma severity, control, and exacerbations: Document presented for the World Health Organization Consultation on Severe Asthma. J. Allergy Clin. Immunol. 126:926–938.

Brusselle G.G., VanderStichele C., Jordens P., Deman R., Slabbynck H., Ringoet V., Verleden G., Demedts I.K., Verhamme K., Delporte A., Demeyere B., Claeys G., Boelens J., Padalko E., Verschakelen J., Van Maele G., Deschepper E., and Joos G.F.P. 2013. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): A multicentre randomised double-blind placebo-controlled trial. Thorax. 68:322–329.

Busse W.W. 2019. Biological treatments for severe asthma: A major advance in asthma care. Allergol. Int. 68:158–166.

Caminati M., Senna G., Stefanizzi G., Bellamoli R., Longhi S., Chieco-Bianchi F., Guarnieri G., Tognella S., Olivieri M., Micheletto C., Festi G., Bertocco E., Mazza M., Rossi A., and Vianello A. 2016. Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience. BMC Pulm. Med. 16:1–9.

Carr T.F. and Kraft M. 2017. Management of severe asthma before referral to the severe asthma specialist. J. Allergy Clin. Immunol. Pract. 5:877–886.

Casale T.B., Bateman E.D., Vandewalker M., Virchow J.C., Schmidt H., Engel M., Moroni-Zentgraf P., and Kerstjens H.A.M. 2018. Tiotropium respimat add-on is efficacious in symptomatic asthma, independent of T2 Phenotype. J. Allergy Clin. Immunol. Pract. 6:923–935.

Castro M., Rubin A., Laviolette M., Fiterman J., de Andrade Lima M., and Shah P. 2010. Asthma intervention research 2 (AIR2) trial. Am. J. Respir. Crit. Care Med. 181:116–124.

Castro M., Corren J., Pavord I.D., Maspero J., Wenzel S., Rabe K.F., Busse W.W., Ford L., Sher L., FitzGerald J.M., Katelaris C., Tohda Y., Zhang B., Staudinger H., Pirozzi G., Amin N., Ruddy M., Akinlade B., Khan A., Chao J., Martincova R., Graham N.M.H., Hamilton J.D., Swanson B.N., Stahl N., Yancopoulos G.D., and Teper A. 2018. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N. Engl. J. Med. 378:2486–2496.

Chen R., Smith S.G., Salter B., El-Gammal A., Oliveria J.P., Obminski C., Watson R., O’Byrne P.M., Gauvreau G.M., and Sehmi R. 2017. Allergen-induced increases in sputum levels of group 2 innate lymphoid cells in subjects with asthma. Am. J. Respir. Crit. Care Med. 196:700–712.

Chung K.F., Wenzel S.E., Brozek J.L., Bush A., Castro M., Sterk P.J., Adcock I.M., Bateman E.D., Bel E.H., Bleecker E.R., Boulet L.P., Brightling C., Chanez P., Dahlen S.E., Djukanovic R., Frey U., Gaga M., Gibson P., Hamid Q., Jajour N.N., Mauad T., Sorkness R.L., and Teague W.G. 2014. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur. Respir. J. 43:343–373.

Corrigan C.J. 2002. Asthma refractory to glucocorticoids: The role of newer immunosuppressants. Am. J. Respir. Med. 1:47–54.

De Groot J.C., Brinke A., Ten, and Bel E.H.D. 2015. Management of the patient with eosinophilic asthma: A new era begins. ERJ Open Res. 1:00024-2015.

Dweik R.A., Boggs P.B., Erzurum S.C., Irvin C.G., Leigh M.W., Lundberg J.O., Olin A.C., Plummer A.L., and Taylor D.R. 2011. An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am. J. Respir. Crit. Care Med. 184:602–615.

Fahy J. V. 2015. Type 2 inflammation in asthma-present in most, absent in many. Nat. Rev. Immunol. 15:57–65.

Farne H.A., Wilson A., Powell C., Bax L., and Milan S.J. 2017. Anti-IL5 therapies for asthma. Cochrane Database Syst. Rev. 9:CD010834.

FDA1. 2004, revised February 2019. Highlights of prescribing information for SPIRIVA RESPIMAT. [Online]. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021936s012lbl.pdf [accessed October 2019].

FDA2. 2003, revised May 2019. Highlights of prescribing information for XOLAIR. [Online]. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103976s5234lbl.pdf [accessed October 2019].

FDA3. 2015, revised September 2019. Highlights of prescribing information for NUCALA. [Online]. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125526s012,761122s002s003lbl.pdf [accessed October 2019].

FDA4. 2016, revised January 2019. Highlights of prescribing information for CINQAIR. [Online]. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/0761033s010lbl.pdf [accessed October 2019].

FDA5. 2017, revised October 2019. Highlights of prescribing information for FASENRA. [Online]. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761070s005lbl.pdf [accessed October 2019].

FDA6. 2017, revised June 2019. Highlights of prescribing information for DUPIXENT. [Online]. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761055s014lbl.pdf [accessed October 2019].

FDA7. 27 April 2010. Premarket approval (PMA) of Alair bronchial thermoplasty system. [Online]. Available from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P080032 [accessed October 2019].

FitzGerald J.M., Bleecker E.R., Nair P., Korn S., Ohta K., Lommatzsch M., Ferguson G.T., Busse W.W., Barker P., Sproule S., Gilmartin G., Werkström V., Aurivillius M., and Goldman M. 2016. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 388:2128–2141.

FitzGerald J.M., Bleecker E.R., Menzies-Gow A., Zangrilli J.G., Hirsch I., Metcalfe P., Newbold P., and Goldman M. 2018. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir. Med. 6:51–64.

Fitzpatrick A.M. and Moore W.C. 2017. Severe asthma phenotypes — How should they guide evaluation and treatment? J. Allergy Clin. Immunol. Pract. 5:901–908.

Gielen V., Johnston S.L., and Edwards M.R. 2010. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur. Respir. J. 36:646–654.

GINA. 2019. Global strategy for asthma management and prevention (2019 update). [Online]. Available from https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf [accessed October 2019].

Good J.T., Kolakowski C.A., Groshong S.D., Murphy J.R., and Martin R.J. 2012. Refractory asthma: Importance of bronchoscopy to identify phenotypes and direct therapy. Chest. 141:599–606.

Haldar, P., Pavord, I.D., Shaw, D.E., Berry, M.A., Thomas, M., Brightling, C.E., Wardlaw, A.J., and Green, R.H. 2008. Cluster analysis and clinical asthma phenotypes. Am. J. Respir. Crit. Care Med.

Hamelmann E. 2018. Managing severe asthma: A role for the long-acting Muscarinic Antagonist Tiotropium. Biomed Res. Int. 2018:1–9.

Hamelmann E., Bateman E.D., Vogelberg C., Szefler S.J., Vandewalker M., Moroni-Zentgraf P., Avis M., Unseld A., Engel M., and Boner A.L. 2016. Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial. J. Allergy Clin. Immunol. 138:441–450.

Hamelmann E., Bernstein J.A., Vandewalker M., Moroni-Zentgraf P., Verri D., Unseld A., Engel M., and Boner A.L. 2017. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma. Eur. Respir. J. 49:1601100.

Hanania N.A., Alpan O., Hamilos D.L., Condemi J.J., Reyes-Rivera I., Zhu J., Rosen K.E., Eisner M.D., Wong D.A., and Busse W. 2011. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: A randomized trial. Ann. Intern. Med. 154:573–582.

Hanania N.A., Korenblat P., Chapman K.R., Bateman E.D., Kopecky P., Paggiaro P., Yokoyama A., Olsson J., Gray S., Holweg C.T.J., Eisner M., Asare C., Fischer S.K., Peng K., Putnam W.S., and Matthews J.G. 2016. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): Replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir. Med. 4:781–796.

Hazenberg M.D. and Spits H. 2014. Human innate lymphoid cells. Blood. 124:700–709.

Hiles, S.A., McDonald, V.M., Guilhermino, M., Brusselle, G.G., and Gibson, P.G. 2019. Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis. Eur. Respir. J.

Hirose K., Iwata A., Tamachi T., and Nakajima H. 2017. Allergic airway inflammation: Key players beyond the Th2 cell pathway. Immunol. Rev. 278:145–161.

Hoyte F.C.L., Gross L.M., and Katial R.K. 2018. Exhaled nitric oxide: An update. Immunol. Allergy Clin. North Am. 38:573–585.

Inoue Y., Izuhara K., Ohta S., Ono J., and Shimojo N. 2015. No increase in the serum periostin level is detected in elementary school-age children with allergic diseases. Allergol. Int. 64:289–290.

Izuhara K., Conway S.J., Moore B.B., Matsumoto H., Holweg C.T.J., Matthews J.G., and Arron J.R. 2016. Roles of periostin in respiratory disorders. Am. J. Respir. Crit. Care Med. 193:949–956.

Jatakanon A., Lim S., and Barnes P.J. 2000. Changes in sputum eosinophils predict loss of asthma control. Am. J. Respir. Crit. Care Med. 161:64–72.

Kaur R. and Chupp G. 2019. Phenotypes and endotypes of adult asthma: Moving toward precision medicine. J. Allergy Clin. Immunol. 144:1–12.

Kerstjens H.A.M., Engel M., Dahl R., Paggiaro P., Beck E., Vandewalker M., Sigmund R., Seibold W., Moroni-Zentgraf P., and Bateman E.D. 2012. Tiotropium in asthma poorly controlled with standard combination therapy. N. Engl. J. Med. 367:1198–1207.

Kerstjens H.A.M., Moroni-Zentgraf P., Tashkin D.P., Dahl R., Paggiaro P., Vandewalker M., Schmidt H., Engel M., and Bateman E.D. 2016. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. Respir. Med. 117:198–206.

Kew K.M., Undela K., Kotortsi I., and Ferrara G. 2015. Macrolides for chronic asthma. Cochrane Database Syst Rev. 15: CD002997.

Kharitonov S.A., Yates D., Robbins R.A., Barnes P.J., Logan-Sinclair R., and Shinebourne E.A. 1994. Increased nitric oxide in exhaled air of asthmatic patients. Lancet. 343:133–135.

Krings J.G., McGregor M.C., Bacharier L.B., and Castro M. 2019. Biologics for severe asthma: Treatment-specific effects are important in choosing a specific agent. J. Allergy Clin. Immunol. Pract. 7:1379–1392.

Lang D.M. 2015. Severe asthma: Epidemiology, burden of illness, and heterogeneity. Allergy Asthma Proc. 36:418–424.

Lefaudeux D., De Meulder B., Loza M.J., Peffer N., Rowe A., Baribaud F., Bansal A.T., Lutter R., Sousa A.R., Corfield J., Pandis I., Bakke P.S., Caruso M., Chanez P., Dahlén S.E., Fleming L.J., Fowler S.J., Horvath I., Krug N., Montuschi P., Sanak M., Sandstrom T., Shaw D.E., Singer F., Sterk P.J., Roberts G., Adcock I.M., Djukanovic R., Auffray C., Chung K.F., Adriaens N., Ahmed H., Aliprantis A., Alving K., Badorek P., Balgoma D., Barber C., Bautmans A., Behndig A.F., Bel E., Beleta J., Berglind A., Berton A., Bigler J., Bisgaard H., Bochenek G., Boedigheimer M.J., Bøonnelykke K., Brandsma J., Braun A., Brinkman P., Burg D., Campagna D., Carayannopoulos L., Carvalho da Purfição Rocha J.P., Chaiboonchoe A., Chaleckis R., Coleman C., Compton C., D’Amico A., Dahlén B., De Alba J., de Boer P., De Lepeleire I., Dekker T., Delin I., Dennison P., Dijkhuis A., Draper A., Edwards J., Emma R., Ericsson M., Erpenbeck V., Erzen D., Faulenbach C., Fichtner K., Fitch N., Flood B., Frey U., Gahlemann M., Galffy G., Gallart H., Garret T., Geiser T., Gent J., Gerhardsson de Verdier M., Gibeon D., Gomez C., Gove K., Gozzard N., Guo Y.K., Hashimoto S., Haughney J., Hedlin G., Hekking P.P., Henriksson E., Hewitt L., Higgenbottam T., Hoda U., Hohlfeld J., Holweg C., Howarth P., Hu R., Hu S., Hu X., Hudson V., James A.J., Kamphuis J., Kennington E.J., Kerry D., Klüglich M., Knobel H., Knowles R., Knox A., Kolmert J., Konradsen J., Kots M., Krueger L., Kuo S., Kupczyk M., Lambrecht B., Lantz A.S., Larsson L., Lazarinis N., Lone-Satif S., Marouzet L., Martin J., Masefield S., Mathon C., Matthews J.G., Mazein A., Meah S., Maiser A., Menzies-Gow A., Metcalf L., Middelveld R., Mikus M., Miralpeix M., Monk P., Mores N., Murray C.S., Musial J., Myles D., Naz S., Nething K., Nicholas B., Nihlen U., Nilsson P., Nordlund B., Östling J., Pacino A., Pahus L., Palkonnen S., Pavlidis S., Pennazza G., Petrén A., Pink S., Postle A., Powel P., Rahman-Amin M., Rao N., Ravanetti L., Ray E., Reinke S., Reynolds L., Riemann K., Riley J., Robberechts M., Roberts A., Rossios C., Russell K., Rutgers M., Santini G., Sentoninco M., Schoelch C., Schofield J.P.R., Seibold W., Sigmund R., Sjödin M., Skipp P.J., Smids B., Smith C., Smith J., Smith K.M., Söderman P., Sogbesan A., Staykova D., Strandberg K., Sun K., Supple D., Szentkereszty M., Tamasi L., Tariq K., Thörngren J.O., Thornton B., Thorsen J., Valente S., van Aalderenm W., van de Pol M., van Drunen K., van Geest M., Versnel J., Vestbo J., Vink A., Vissing N., von Garnier C., Wagerner A., Wagers S., Wald F., Walker S., Ward J., Weiszhart Z., Wetzel K., Wheelock C.E., Wiegman C., Williams S., Wilson S.J., Woosdcock A., Yang X., Yeyashingham E., Yu W., Zetterquist W., and Zwinderman K. 2017. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J. Allergy Clin. Immunol. 139:1797–1807.

Leuppi J.D., Salome C.M., Jenkins C.R., Anderson S.D., Xuan W., Marks G.B., Koskela H., Brannan J.D., Freed R., Andersson M., Chan H.K., and Woolcock A.J. 2001. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am. J. Respir. Crit. Care Med. 163:406–412.

Li N., Qiu R., Yang Z., Li J., Chung K.F., Zhong N., and Zhang Q. 2017. Sputum microbiota in severe asthma patients: Relationship to eosinophilic inflammation. Respir. Med. 131:192–198.

Lopes Dos Santos Santiago G., Brusselle G., Dauwe K., Deschaght P., Verhofstede C., Vaneechoutte D., Deschepper E., Jordens P., Joos G., and Vaneechoutte M. 2017. Influence of chronic azithromycin treatment on the composition of the oropharyngeal microbial community in patients with severe asthma. BMC Microbiol. 17:1–12.

Mansur A.H., Srivastava S., Mitchell V., Sullivan J., and Kasujee I. 2017. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety. Respir. Med. 124:36–43.

Maselli D.J., Velez M.I., and Rogers L. 2016. Reslizumab in the management of poorly controlled asthma: The data so far. J. Asthma Allergy 9:155–162.

McBrien C.N. and Menzies-Gow A. 2017. The biology of eosinophils and their role in asthma. Front. Med. 4:93.

McQueen R.B., Sheehan D.N., Whittington M.D., van Boven J.F.M., and Campbell J.D. 2018. Cost-effectiveness of biological asthma treatments: A systematic review and recommendations for future economic evaluations. Pharmacoeconomics. 36:957–971.

Medrek S.K., Parulekar A.D., and Hanania N.A. 2017. Predictive biomarkers for asthma therapy. Curr. Allergy Asthma Rep. 17:69.

Mitchell P.D. and O’Byrne P.M. 2017. Epithelial-derived cytokines in asthma. Chest. 151:1338–1344.

Moore W.C., Meyers D.A., Wenzel S.E., Teague W.G., Li H., Li X., D’Agostino R., Castro M., Curran-Everett D., Fitzpatrick A.M., Gaston B., Jarjour N.N., Sorkness R., Calhoun W.J., Chung K.F., Comhair S.A.A., Dweik R.A., Israel E., Peters S.P., Busse W.W., Erzurum S.C., and Bleecker E.R. 2010. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am. J. Respir. Crit. Care Med. 181:315–323.

Moore W.C., Evans M.D., Bleecker E.R., Busse W.W., Calhoun W.J., Castro M., Chung K.F., Erzurum S.C., Curran-Everett D., Dweik R.A., Gaston B., Hew M., Israel E., Mayse M.L., Pascual R.M., Peters S.P., Silveira L., Wenzel S.E., and Jarjour N.N. 2011. Safety of investigative bronchoscopy in the Severe Asthma Research Program. J. Allergy Clin. Immunol. 128:328–336.e3.

Nair P., Wenzel S., Rabe K.F., Bourdin A., Lugogo N.L., Kuna P., Barker P., Sproule S., Ponnarambil S., and Goldman M. 2017. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N. Engl. J. Med. 376:2448–2458.

National Heart, Lung, and Blood Institute. 2007. National asthma education and prevention program: Expert panel report III: Guidelines for the diagnosis and management of asthma. J Allergy Clin Immunol. 120:S94–S138.

Normansell R., Walker S., Milan S.J., Walters E.H., and Nair P. 2014. Omalizumab for asthma in adults and children. Cochrane Database Syst. Rev. 13: CD003559.

Ohta S., Oda N., Yokoe T., Tanaka A., Yamamoto Y., Watanabe Y., Minoguchi K., Ohnishi T., Hirose T., Nagase H., Ohta K., and Adachi M. 2010. Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma. Clin. Exp. Allergy 40:1266–1275.

Opina M.T.D. and Moore W.C. 2017. Phenotype-driven therapeutics in severe asthma. Curr. Allergy Asthma Rep. 17:10.

Ortega H.G., Yancey S.W., Mayer B., Gunsoy N.B., Keene O.N., Bleecker E.R., Brightling C.E., and Pavord I.D. 2016. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: A secondary analysis of the DREAM and MENSA studies. Lancet Respir. Med. 4:549–556.

Pavord I.D., Afzalnia S., Menzies-Gow A., and Heaney L.G. 2017. The current and future role of biomarkers in type 2 cytokine-mediated asthma management. Clin. Exp. Allergy 47:148–160.

Peters S.P., Kunselman S.J., Icitovic N., Moore W.C., Pascual R., Ameredes B.T., Boushey H.A., Calhoun W.J., Castro M., Cherniack R.M., Craig T., Denlinger L., Engle L.L., DiMango E.A., Fahy J.V., Israel E., Jarjour N., Kazani S.D., Kraft M., Lazarus S.C., Lemanske R.F., Lugogo N., Martin R.J., Meyers D.A., Ramsdell J., Sorkness C.A., Sutherland E.R., Szefler S.J., Wasserman S.I., Walter M.J., Wechsler M.E., Chinchilli V.M., and Bleecker E.R. 2010. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N. Engl. J. Med. 363:1715–1726.

Petsky H.L., Kew K.M., Turner C., and Chang A.B. 2016a. Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database Syst Rev. 11: CD011440.

Petsky H.L., Kew K.M., Turner C., Kynaston J.A., and Chang A.B. 2016b. Exhaled nitric oxide (FeNO) levels to guide treatment for children with asthma: A cochrane systematic review. Eur. Respir. J. 48:PA4373.

Petsky H.L., Li A., and Chang A.B. 2017. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database Syst. Rev. 2017. 8: CD005603.

Price D.B., Rigazio A., Campbell J.D., Bleecker E.R., Corrigan C.J., Thomas M., Wenzel S.E., Wilson A.M., Small M.B., Gopalan G., Ashton V.L., Burden A., Hillyer E.V., Kerkhof M., and Pavord I.D. 2015. Blood eosinophil count and prospective annual asthma disease burden: A UK cohort study. Lancet Respir. Med. 3:849–858.

Rabe K.F., Nair P., Brusselle G., Maspero J.F., Castro M., Sher L., Zhu H., Hamilton J.D., Swanson B.N., Khan A., Chao J., Staudinger H., Pirozzi G., Antoni C., Amin N., Ruddy M., Akinlade B., Graham N.M.H., Stahl N., Yancopoulos G.D., and Teper A. 2018. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N. Engl. J. Med. 378:2475–2485.

Ribeiro C.M.P., Hurd H., Wu Y., Martino M.E.B., Jones L., Brighton B., Boucher R.C., and O’Neal W.K. 2009. Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia. PLoS ONE. 4: e5806.

Schleich F., Brusselle G., Louis R., Vandenplas O., Michils A., Pilette C., Peche R., Manise M., and Joos G. 2014. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir. Med. 108:1723–1732.

Shaw D.E., Sousa A.R., Fowler S.J., Fleming L.J., Roberts G., Corfield J., Pandis I., Bansal A.T., Bel E.H., Auffray C., Compton C.H., Bisgaard H., Bucchioni E., Caruso M., Chanez P., Dahlén B., Dahlen S.E., Dyson K., Frey U., Geiser T., De Verdier M.G., Gibeon D., Guo Y.K., Hashimoto S., Hedlin G., Jeyasingham E., Hekking P.P.W., Higenbottam T., Horváth I., Knox A.J., Krug N., Erpenbeck V.J., Larsson L.X., Lazarinis N., Matthews J.G., Middelveld R., Montuschi P., Musial J., Myles D., Pahus L., Sandström T., Seibold W., Singer F., Strandberg K., Vestbo J., Vissing N., Von Garnier C., Adcock I.M., Wagers S., Rowe A., Howarth P., Wagener A.H., Djukanovic R., Sterk P.J., and Chung K.F. 2015. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur. Respir. J. 46:1308–1321.

Sonnenberg G.F. and Hepworth M.R. 2019. Functional interactions between innate lymphoid cells and adaptive immunity. Nat. Rev. Immunol. 19:599–613.

Spagnolo P., Fabbri L.M., and Bush A. 2013. Long-term macrolide treatment for chronic respiratory disease. Eur. Respir. J. 42:239–251.

Szefler S.J., Murphy K., Harper T., Boner A., Laki I., Engel M., El Azzi G., Moroni-Zentgraf P., Finnigan H., and Hamelmann E. 2017. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. J. Allergy Clin. Immunol. 140:1277–1287.

Szefler S.J., Vogelberg C., Bernstein J.A., Goldstein S., Mansfield L., Zaremba-Pechmann L., Engel M., and Hamelmann E. 2019. Tiotropium is efficacious in 6- to 17-year-olds with asthma, independent of T2 phenotype. J. Allergy Clin. Immunol. Pract. 7:2286–2295.e4.

Tadrous M., Khuu W., Lebovic G., Stanbrook M.B., Martins D., Paterson J.M., Mamdani M.M., Juurlink D.N., and Gomes T. 2018. Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma. Ann. Allergy, Asthma Immunol. 120:59–65.e2.

Tajiri T., Matsumoto H., Gon Y., Ito R., Hashimoto S., Izuhara K., Suzukawa M., Ohta K., Ono J., Ohta S., Ito I., Oguma T., Inoue H., Iwata T., Kanemitsu Y., Nagasaki T., Niimi A., and Mishima M. 2016. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma. Allergy Eur. J. Allergy Clin. Immunol. 71:1472–1479.

Takayama G., Arima K., Kanaji T., Toda S., Tanaka H., Shoji S., McKenzie A.N.J., Nagai H., Hotokebuchi T., and Izuhara K. 2006. Periostin: A novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J. Allergy Clin. Immunol. 118:98–104.

Tan L.D., Yoneda K.Y., Louie S., Hogarth D.K., and Castro M. 2019. Bronchial thermoplasty: A decade of experience: State of the art. J. Allergy Clin. Immunol. Pract. 7:71–80.

Taylor D.R. 2006. Nitric oxide as a clinical guide for asthma management. J. Allergy Clin. Immunol. 117:259–262.

Taylor S.L., Leong L.E.X., Mobegi F.M., Choo J.M., Wesselingh S., Yang I.A., Upham J.W., Reynolds P.N., Hodge S., James A.L., Jenkins C., Peters M.J., Baraket M., Marks G.B., Gibson P.G., Rogers G.B., and Simpson J.L. 2019. Long-term azithromycin reduces haemophilus influenzae and increases antibiotic resistance in severe asthma. Am. J. Respir. Crit. Care Med. 200:309–317.

Tiotiu A. 2018. Biomarkers in asthma: state of the art. Asthma Res. Pract. 4:10.

Tyler S.R. and Bunyavanich S. 2019. Leveraging -omics for asthma endotyping. J. Allergy Clin. Immunol. 144:13–23.

Veen J.C.C.M., Smits H.H., Hiemstra P.S., Zwinderman A.E., Sterk P.J., and Bel E.H. 1999. Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal. Am. J. Respir. Crit. Care Med. 160:93–99.

Vonk J.M., Jongepier H., Panhuysen C.I.M., Schouten J.P., Bleecker E.R., and Postma D.S. 2003. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax. 58:322–327.

Wagener A.H., De Nijs S.B., Lutter R., Sousa A.R., Weersink E.J.M., Bel E.H., and Sterk P.J. 2015. External validation of blood eosinophils, FENO and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 70:115–120.

Wechsler M.E., Laviolette M., Rubin A.S., Fiterman J., Lapa e Silva J.R., Shah P.L., Fiss E., Olivenstein R., Thomson N.C., Niven R.M., Pavord I.D., Simoff M., Hales J.B., McEvoy C., Slebos D.-J., Holmes M., Phillips M.J., Erzurum S.C., Hanania N.A., Sumino K., Kraft M., Cox G., Sterman D.H., Hogarth K., Kline J.N., Mansur A.H., Louie B.E., Leeds W.M., Barbers R.G., Austin J.H.M., Shargill N.S., Quiring J., Armstrong B., and Castro M. 2013. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J. Allergy Clin. Immunol. 132:1295–1302.e3.

Wenzel S., Ford L., Pearlman D., Spector S., Sher L., Skobieranda F., Wang L., Kirkesseli S., Rocklin R., Bock B., Hamilton J., Ming J.E., Radin A., Stahl N., Yancopoulos G.D., Graham N., and Pirozzi G.2013. Dupilumab in persistent asthma with elevated eosinophil levels. N. Engl. J. Med. 368:2455–2466.

Winkler C., Hochdörfer T., Israelsson E., Hasselberg A., Cavallin A., Thörn K., Muthas D., Shojaee S., Lüer K., Müller M., Mjösberg J., Vaarala O., Hohlfeld J., and Pardali K. 2019. Activation of group 2 innate lymphoid cells after allergen challenge in asthmatic patients. J. Allergy Clin. Immunol. 144:61–69.e7.

Zazzali J.L., Raimundo K.P., Trzaskoma B., Rosén K.E., and Schatz M. 2015. Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results. Allergy Asthma Proc. 36:283–292.

Zimmermann G.S., Neurohr C., Villena-Hermoza H., Hatz R., and Behr J. 2009. Anti-inflammatory effects of antibacterials on human bronchial epithelial cells. Respir. Res. 10:4–7.

Zissler U.M., Esser-Von Bieren J., Jakwerth C.A., Chaker A.M., and Schmidt-Weber C.B. 2016. Current and future biomarkers in allergic asthma. Allergy. 71:475–494.